Literature DB >> 7748520

Neocortical neurotransmitter markers in Huntington's disease.

S J Pearson1, G P Reynolds.   

Abstract

Several neurotransmitter markers were determined in post mortem tissue from temporal and frontal cortex in Huntington's disease in order to identify and understand the specific neuronal losses that occur in the neocortex in this disease. Decreases in GABA and glutamate concentrations were identified, together with increases in metabolites of dopamine and 5-hydroxytryptamine, indicative of regulatory changes presumably induced by the neuronal deficits. There is also evidence for abnormal cortical tryptophan metabolism. These changes may well contribute to some of the behavioural symptoms of the disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7748520     DOI: 10.1007/BF01276536

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  53 in total

1.  Neurochemical abnormalities in Huntington's disease: neurotoxic mechanisms and neurotransmitter changes.

Authors:  G P Reynolds; S J Pearson
Journal:  J Neurol Sci       Date:  1992-12       Impact factor: 3.181

Review 2.  Perspectives on a time-dependent model of neuroleptic action.

Authors:  D Pickar
Journal:  Schizophr Bull       Date:  1988       Impact factor: 9.306

3.  Decreased glutamic acid and increased 5-hydroxytryptamine in Huntington's disease brain.

Authors:  G P Reynolds; S J Pearson
Journal:  Neurosci Lett       Date:  1987-07-22       Impact factor: 3.046

4.  Elevated serotonin and reduced dopamine in subregionally divided Huntington's disease striatum.

Authors:  S J Kish; K Shannak; O Hornykiewicz
Journal:  Ann Neurol       Date:  1987-09       Impact factor: 10.422

5.  Enzymes associated with the metabolism of catecholamines, acetylcholine and gaba in human controls and patients with Parkinson's disease and Huntington's chorea.

Authors:  P L McGeer; E G McGeer
Journal:  J Neurochem       Date:  1976-01       Impact factor: 5.372

6.  Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain.

Authors:  T L Perry; S Hansen; M Kloster
Journal:  N Engl J Med       Date:  1973-02-15       Impact factor: 91.245

7.  Parkinson's disease and dementia: norepinephrine and dopamine in locus ceruleus.

Authors:  R Cash; T Dennis; R L'Heureux; R Raisman; F Javoy-Agid; B Scatton
Journal:  Neurology       Date:  1987-01       Impact factor: 9.910

8.  Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex.

Authors:  M F Beal; W R Matson; E Storey; P Milbury; E A Ryan; T Ogawa; E D Bird
Journal:  J Neurol Sci       Date:  1992-03       Impact factor: 3.181

9.  Cholecystokinin receptors are decreased in basal ganglia and cerebral cortex of Huntington's disease.

Authors:  S E Hays; F K Goodwin; S M Paul
Journal:  Brain Res       Date:  1981-11-30       Impact factor: 3.252

10.  Differential cognitive impairment in Alzheimer's disease and Huntington's disease.

Authors:  J Brandt; S E Folstein; M F Folstein
Journal:  Ann Neurol       Date:  1988-06       Impact factor: 10.422

View more
  1 in total

1.  Disease-modifying effects of ganglioside GM1 in Huntington's disease models.

Authors:  Melanie Alpaugh; Danny Galleguillos; Juan Forero; Luis Carlos Morales; Sebastian W Lackey; Preeti Kar; Alba Di Pardo; Andrew Holt; Bradley J Kerr; Kathryn G Todd; Glen B Baker; Karim Fouad; Simonetta Sipione
Journal:  EMBO Mol Med       Date:  2017-11       Impact factor: 12.137

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.